Skip to content
Prazosin
Minipress, Minizide (prazosin) is a small molecule pharmaceutical. Prazosin was first approved as Minizide on 1982-01-01. It is used to treat hypertension, prostatic hyperplasia, raynaud disease, and urinary retention in the USA. The pharmaceutical is active against alpha-1D adrenergic receptor, alpha-1A adrenergic receptor, and alpha-1B adrenergic receptor. In addition, it is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, alpha-2C adrenergic receptor, and ribosyldihydronicotinamide dehydrogenase [quinone].
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Minipress (generic drugs available since 1988-09-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Polythiazide
+
Prazosin hydrochloride
Tradename
Company
Number
Date
Products
MINIZIDEMylanN-017986 DISCN1982-01-01
3 products
Hide discontinued
Prazosin hydrochloride
Tradename
Company
Number
Date
Products
MINIPRESSMylanN-017442 RX1982-01-01
3 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
minipressNew Drug Application2019-12-16
prazosin hydrochlorideANDA2023-06-06
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
prostatic hyperplasiaEFO_0000284D011470N40
raynaud diseaseEFO_1001145D011928I73.0
urinary retentionHP_0000016D016055R33
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02C: Antiadrenergic agents, peripherally acting
— C02CA: Alpha-adrenoreceptor antagonists, peripherally acting
— C02CA01: Prazosin
— C02L: Antihypertensives and diuretics in combination
— C02LE: Alpha-adrenoreceptor antagonists and diuretics
— C02LE01: Prazosin and diuretics
HCPCS
No data
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePRAZOSIN
INNprazosin
Description
Prazosin is a member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a member of piperazines, a member of quinazolines, a member of furans, a monocarboxylic acid amide and an aromatic ether.
Classification
Small molecule
Drug classantihypertensives (prazosin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
Identifiers
PDB3OWX
CAS-ID19216-56-9
RxCUI8629
ChEMBL IDCHEMBL2
ChEBI ID8364
PubChem CID4893
DrugBankDB00457
UNII IDXM03YJ541D (ChemIDplus, GSRS)
Target
Agency Approved
ADRA1D
ADRA1D
ADRA1A
ADRA1A
ADRA1B
ADRA1B
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
146
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Q9NPY0
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (P97714)
Alternate
ADRA2B
ADRA2B
ADRA2A
ADRA2A
ADRA2C
ADRA2C
NQO2
NQO2
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
151
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Q9BZK0
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,637 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,379 adverse events reported
View more details